Medical device for analyte monitoring and drug delivery
The invention relates to an ingestible, implantable or wearable medical device comprising a microarray which comprises a bioactive agent capable of interacting with a disease marker biological analyte; a reservoir which comprises at least one therapeutic agent and is capable of releasing the therapeutic agent(s) from the medical device; and a plurality of microchips comprising a microarray scanning device capable of obtaining physical parameter data of an interaction between the disease marker biological analyte with the bioactive agent; a biometric recognition device capable of comparing the physical parameter data with an analyte interaction profile; optionally a therapeutic agent releasing device capable of controlling release of the therapeutic agent from the reservoirs; an interface device capable of facilitating communications between the microarray scanning device, biometric recognition device and the therapeutic agent releasing device; and an energy source to power the medical device. Specifically, the invention relates to a medical device capable of detecting an analyte in a bodily fluid comprising at least one microneedle capable of obtaining a sample of a bodily fluid, a first microchannel through which the sample flows and is in fluid communication with the at least one microneedle, a second microchannel in fluid communication with the first microchannel, through which a buffer flows, wherein the second channel comprises a microarray with a bioactive agent, a microarray scanning device to detect an interaction between the bioactive agent and the analyte in the bodily fluid; and an interface device.
1. A method of detecting an interaction if of an ingestible medical device with a gastric fluid comprising:
administering an ingestible medical device to a subject, wherein the ingestible medical device comprises:
a microchip enclosed in said ingestible medical device,
wherein said device is configured to interact with the gastric fluid when ingested by the subject;
said microchip comprising an interface device that is configured to wirelessly transmit to an external device located outside the subject a signal that is generated upon interaction of the device with the gastric fluid,
a biocompatible coating covering at least a portion of the device, wherein a) a portion of the coating is characterized by interconnected pores of sufficient size to allow for flow of bodily fluids into the ingestible medical device and b) another portion of the coating covering a larger portion of device that is not porous;
operating the ingestible medical device to transmit the signal upon interaction of the device with the gastric fluid.
2. The method of claim 1 further comprising releasing a therapeutic agent to the subject.
3. The method of claim 1 wherein the external device comprises a biometric recognition device that analyzes the signal and determines the absence, presence, or quantity of an analyte where the device interacts with the gastric fluid.
4. The method of claim 3 wherein the biometric recognition device matches data provided by the signal to a known analyte interaction profile to determine the presence, absence, or quantity of the analyte.
5. The method of claim 3 wherein the biometric recognition device is worn on the skin as a patch.
6. The method of claim 1 wherein the signal is generated based upon natural electric currents in the body.
7. The method of claim 1 wherein said signal is indicative of bio-electric, bio-magnetic, or biochemical characteristics of the device's interaction with the gastric fluid.
8. The method of claim 1 further comprising measuring a physiological condition of the subject.
9. The method of claim 8 wherein the interface device is configured to transmit one or more physiological conditions.
10. The method of claim 2 wherein releasing the therapeutic agent releasing comprises release from one or more reservoirs of therapeutic agent of the ingestible medical device.
11. The method of claim 10 wherein releasing the therapeutic agent signals the external device of the status of therapeutic agent release.
12. The method of claim 1 wherein the external device is a computer.
13. The method of claim 1 wherein the external device is in communication with an external network.
14. The method of claim 1 comprises using a personal area network for the ingestible medical device to communicate with the external device.